Led · Series A · Jun 2026

Vedana is advancing a portfolio of internally discovered, long-acting, subcutaneously delivered antibody therapies designed to prevent migraine by targeting PACAP and combinatorial PACAP/CGRP biology. Its lead program is an anti-PACAP antibody and its second program is a bispecific antibody that targets both PACAP and CGRP. The company emphasizes highly potent, long half-life antibodies intended for self-injection at home. Vedana was founded and built by experienced migraine drug developers and industry leaders who worked on approved CGRP medicines and emerging PACAP approaches. The company launched from stealth and is based in Seattle. Vedana announced a $46 million Series A to fund advancement of its pipeline.

Led · Series A · May 2026

Oorja Bio is a clinical-stage company focused on developing therapies that target the underlying pathophysiology of fibrotic and cardiopulmonary diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF). Its lead candidate, ORJ-001, is a first-in-class peptide therapeutic administered subcutaneously that acts as an agonist of β1 integrin to restore alveolar epithelial type 2 (AEC2) cell function, promote alveolar repair, and reduce inflammatory and fibrotic signaling. In preclinical studies in validated animal models, ORJ-001 reversed established fibrosis, regenerated normal lung and alveolar morphology, and produced positive effects on biomarkers of tissue remodeling. Oorja Bio has obtained IND clearance from the U.S. FDA for ORJ-001 and plans to initiate a Phase 2 clinical trial in IPF patients in 2026. The company acquired global rights to ORJ-001 through an in-licensing strategy and intends to build a broader pipeline of therapeutics addressing fibrosis and cardiopulmonary function. Oorja Bio was founded with initial investment from Westlake BioPartners and is based in Houston, TX.

Led · Series A · Sep 2025

AllRock Bio is a Natick, Massachusetts–based clinical-stage biotechnology company focused on cardiopulmonary and fibrotic diseases. Its lead asset, ROC-101, is an orally administered, first-in-class pan-rho-associated protein kinase (ROCK1/2) inhibitor licensed exclusively from Sanofi. Phase 1 data showed favorable safety, tolerability and no associated hypotension, supporting advancement into Phase 2a testing in PAH and ILD-PH patients. The upcoming ROCSTAR Phase 2a trial will study ROC-101 in combination with standard of care and is expected to begin in late 2025. Management includes veterans from CinCor Pharma, which was acquired by AstraZeneca for up to $1.8 billion, providing significant drug-development experience. AllRock was incubated by JucaBio and is building an expanding pipeline of ROCK-targeting therapies to address large unmet needs in life-threatening cardiopulmonary conditions.

Participated · Series D · Jun 2025

Neuron23 is developing NEU-411, a potent, selective, brain-penetrant oral inhibitor of the LRRK2 kinase pathway intended to treat LRRK2-driven Parkinson’s disease. The company is running the global Phase 2 NEULARK clinical trial that prospectively identifies patients with LRRK2-driven disease and randomized them to receive NEU-411 or placebo for a 52-week treatment period. NEULARK is among the first Parkinson’s trials to apply a precision medicine approach and uses Roche’s smartphone-based digital biomarker software to frequently monitor motor and non-motor symptoms. Neuron23 has identified single-nucleotide polymorphisms predicted to drive LRRK2 overactivity in up to 30% of people with idiopathic Parkinson’s disease and includes people with LRRK2 gene mutations in its target population. The company is expanding NEULARK into Israel with clinical sites in Tel Aviv, Jerusalem, and Haifa and recently screened its first patient there. Neuron23 has partnered with Sano Genetics to streamline referrals and offer saliva test kits to identify potential trial participants. The $2.5 million grant from The Michael J. Fox Foundation will support site activation and patient screening for the Israeli expansion.

Participated · Series B · Mar 2025

Latigo Biotherapeutics is a clinical-stage biotech focused on developing best-in-class non-opioid pain medicines that target pain at its source via selective Nav1.8 inhibition. Its lead candidate, LTG-001, is an oral selective Nav1.8 inhibitor for acute pain and reported positive Phase 1 first-in-human results, showing it was well tolerated with rapid absorption. A second oral Nav1.8 inhibitor, LTG-305, is in Phase 1 trials aimed at chronic pain and is being evaluated for safety, tolerability, and pharmacokinetics. The company’s stated goal is to provide effective, rapid-acting pain relief without the risk of addiction. Latigo recently closed a $150 million Series B to support advancement of its Nav1.8 clinical programs and the development of a broader pipeline. The company is based in Thousand Oaks, Calif. Latigo Biotherapeutics is a Thousand Oaks, CA-based clinical-stage biotech focused on non-opioid pain therapeutics that act on the fundamental mechanism of pain transduction. The company uses proprietary in-house technology that applies AI, machine learning, structure-based, and knowledge-based design to generate drugs against targets validated by human genetics. Its lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers intended to treat acute and chronic pain. Latigo also maintains a suite of Nav1.8 inhibitors to address the broader clinical potential of the target and has additional small-molecule discovery programs against genetically identified targets. Leadership changes accompanying the financing include the appointment of Desmond Padhi as interim CEO and Nancy Stagliano as chair of the board. The company intends to use the proceeds to support continued advancement of its portfolio of novel pain therapeutics.